The intervention showed no clear difference in self‐controlled case series ‐ invasive bacterial infections ‐… (low certainty).
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artemether‐lumefantrine (low certainty).
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐unadjusted compared with artesunate‐atovaquone‐proguanil (low certainty).
Atovaquone‐proguanil showed no clear difference in total failure [day 42 PCR‐adjusted compared with artesunate‐atovaquone‐proguanil (moderate certainty).
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artesunate‐atovaquone‐proguanil (moderate certainty).
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artemether‐lumefantrine (low certainty).
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐adjusted compared with artemether‐lumefantrine (low certainty).
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artesunate‐amodiaquine (low certainty).
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐unadjusted compared with artesunate‐amodiaquine (low certainty).
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐adjusted compared with artesunate‐mefloquine (high certainty).
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artesunate‐mefloquine (low certainty).
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artesunate‐atovaquone‐proguanil (low certainty).
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ stoma… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ bowel… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
Neoadjuvant chemotherapy prior to interval surgery (NACT) leads to lower surgically‐related postoperative mortality (28 days to 6 months of… compared with surgery followed by chemotherapy (PDS) (high certainty).